Acutus Medical, Inc. President and CEO Vince Burgess By Jarrett Banks Acutus Medical, Inc. (Nasdaq: AFIB), which focuses on electrophysiology, recently closed its initial public offering, becoming the latest biotech […]

NEW YORK–(BUSINESS WIRE)–Panacea Acquisition Corp. (NYSE: PANA.U) (the “Company”) today announced that, commencing August 21, 2020, holders of the units sold in the Company’s initial public offering of 14,375,000 units […]

LAS VEGAS–(BUSINESS WIRE)–Foley Trasimene Acquisition Corp. II (the “Company”) today announced the pricing of its initial public offering of 130,000,000 units at a price of $10.00 per unit. The Company […]

NEW YORK–(BUSINESS WIRE)–dMY Technology Group, Inc. II (the “Company”) announced today the closing of the issuance of an additional 3,600,00 units pursuant to the full exercise of the underwriters’ over-allotment […]

NEW YORK–(BUSINESS WIRE)–dMY Technology Group, Inc. II (the “Company”) announced today that it closed its initial public offering of 24,000,000 units at a price of $10.00 per unit, including 3,600,000 […]

NEW YORK–(BUSINESS WIRE)–Starboard Value Acquisition Corp. (the “Company” or “SVAC”) today announced that it has filed a registration statement on Form S-1 (the “Registration Statement”) with the Securities and Exchange […]

SAN FRANCISCO–(BUSINESS WIRE)–one, a newly-organized blank check company founded and led by technology industry veteran Kevin Hartz, today announced the pricing of a $200 million initial public offering. The offering […]

NEW YORK–(BUSINESS WIRE)–dMY Technology Group, Inc. II (the “Company”) announced today the pricing of its initial public offering of 24,000,000 units at a price of $10.00 per unit. The units […]

SAN FRANCISCO–(BUSINESS WIRE)–Dragoneer Growth Opportunities Corp. (the “Company”) announced today the pricing of its initial public offering of 60,000,000 units at $10.00 per unit. The units will be listed on […]

CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, […]